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Kawasaki disease (KD) is characterized by systemic vasculitis of unknown etiology. High-dose intravenous immunoglobulin
(IVIG) is the most eﬀective therapy for KD to reduce the prevalence of coronary artery lesion (CAL) formation. Recently, the
α2, 6 sialylated IgG was reported to interact with a lectin receptor, speciﬁc intracellular adhesion molecule-3 grabbing nonintegrin
homolog-related 1 (SIGN-R1) in mice and dendritic cell-speciﬁc intercellular adhesion molecule-3 grabbing nonintegrin (DC-
SIGN)inhuman,andtotriggerananti-inﬂammatorycascade.Thisstudywasconductedtoinvestigatewhetherthepolymorphism
of DC-SIGN (CD209) promoter −336 A/G (rs4804803) is responsible for susceptibility and CAL formation in KD patients using
Custom TaqMan SNP Genotyping Assays. A total of 521 subjects (278KD patients and 243 controls) were investigated to identify
an SNP of rs4804803, and they were studied and showed a signiﬁcant association between the genotypes and allele frequency of
rs4804803 in control subjects and KD patients (P = 0.004 under the dominant model). However, the promoter variant of DC-
SIGN gene was not associated with the occurrence of IVIG resistance, CAL formation in KD. The G allele of DC-SIGN promoter
−336 (rs4804803) is a risk allele in the development of KD.
1.Introduction
Kawasaki disease (KD), mucocutaneous lymphnode syndro-
me, is a systemic vasculitis that predominantly aﬀects chil-
dren under the age of ﬁve years. Although the cause is still
unknown, KD is the most common cause of acquired heart
disease during childhood in the developed countries at this
time. Coronary artery lesions (CAL) are the major complica-
tions of KD. There is a 15–25% chance of CAL developing in
KD patients without early treatment [1]. Although the exact
therapeutic mechanisms have not been fully established,
high-dose intravenous immunoglobulin (IVIG) is the most
eﬀective therapy for KD to reduce the prevalence of CAL [2].
Many potential mechanisms of action for IVIG have
been suggested [3]. Of them, at least three main mechanisms
are suggested to explain the anti-inﬂammatory function of
high dose IVIG: ﬁrst, high-dose IgG saturates the neonatal
FcRs(FcRn)andleadstotheincreasedcatabolismofautoan-
tibodies; second, high-dose IgG saturates the activating Fcγ
receptors (FcγRs) and prevents autoantibody-mediated acti-
vation of leukocytes; third, high-dose IgG increases the cell
surface expression of inhibitory Fcγ receptors [4]. A single,
N-linked glycosylation site exists at the amino acid 297 in the
heavy chain of all IgG subclasses with approximately 10%
terminating in sialic acid [5]. Recently, the α2, 6 sialylated
IgG was reported to interact with a lectin receptor, speciﬁc2 The Scientiﬁc World Journal
intracellular adhesion molecule-3 grabbing nonintegrin
homolog-related 1 (SIGN-R1) in mice and dendritic cell-
speciﬁc intercellular adhesion molecule-3 grabbing non-
integrin (DC-SIGN) in humans, and to trigger an anti-in-
ﬂammatory cascade that promotes the upregulation of in-
hibitory FcγRs on inﬂammatory macrophages [6].
There has been some evidence demonstrating the role of
DC-SIGN promoter variants in the susceptibility to or the
protectionagainstvariousinfectiousdiseases,suchasdengue
fever, tuberculosis, and AIDS [7–9]. However, whether DC-
SIGN promoter variants have eﬀects on susceptibility to KD
is still unknown. Since DC-SIGN, also known as CD209,
is so important for the anti-inﬂammatory functions of
IVIG, it is reasonable to hypothesize that a functional single
nucleotide polymorphism (SNP)in theCD209 moleculewill
be involved in the pathogenesis of KD or response to IVIG
treatment. We hypothesized that the SNP rs4804803 of DC-
SIGN promoter may be involved in the susceptibility to KD,
CAL formation, coronary artery ﬁstula formation, and IVIG
treatmentresponseinKDpatients.Totestthishypothesis,we
conducted a case-control study involving 278 patients with
KD and 243 controls.
2.MaterialsandMethods
2.1. Patients Studied. All patients studied were children who
fulﬁlled the diagnostic criteria for KD and were admitted
for IVIG treatment at Chang Gung Memorial Hospital—
Kaohsiung Medical Center, from 2002 and 2009. All patients
were treated with a single high-dose IVIG (2g/kg) over a 12-
hourperiod[10–12].ThisstudywasapprovedbytheInstitu-
tional Review Board of Chang Gung Memorial Hospital with
writtenconsentstatement.Weexcludedpatientswhodidnot
ﬁt the diagnostic criteria of KD. CAL was deﬁned by the
internal diameter of the coronary artery being greater than
3mm (4mm, if the subject was over the age of 5 years) or the
internal diameter of a segment being at least 1.5 times that of
an adjacent segment, as observed in the echocardiogram [13,
14]. KD patients with coronary artery ectasia or dilatation
which was disappearing within the initial 6–8 weeks after the
onset of illness was deﬁned as transient CAL [3]. The diag-
nosis of coronary artery ﬁstula (CAF) was made mainly by
pulsed Doppler and color ﬂow imaging [15]. IVIG treatment
responsiveness was deﬁned as defevrscence 48hrs after the
completion of IVIG treatment and no fever (temperature,
>38◦C) recurrence for at least 7 days after the initial IVIG
treatment with marked improvement of inﬂammatory signs
[16]. Patients with IVIG resistance received another dose
of IVIG (1-2g/kg) or other anti-inﬂammatory regiments.
Children who were admitted for upper and/or lower respi-
ratory tract infections (including acute bronchiolitis, acute
pharyngitis, acute bronchitis, croup, and acute tonsillitis)
were also collected as control subjects for comparison during
the same study period, as we have previously described [12].
2.2. Genotyping of CD209 rs4804803 SNP. Genomic DNA
was isolated from heparin-anticoagulated blood samples
using a standard phenol-chloroform extraction followed
by 70% alcohol precipitation. Genotyping for the CD209
variant (−336 A/G; rs4804803) was carried out using
Custom TaqMan SNP Genotyping Assays (Applied Biosys-
tems, Foster City, CA, USA). The primer sequences
were 5 -GGACAGTGCTTCCAGGAACT-3  (forward) and
5 -TGTGTTACACCCCCTCCACTAG-3  (reverse). The Taq-
Man minor groove binder probe sequences were 5 -
TACCTGCCTACCCTTG-3  and 5 -CTGCCCACCCTTG-3 .
The probes were labeled with the TaqMan ﬂuorescent dyes
VIC and FAM, respectively. The PCR was conducted in
total volume of 15μL using the following ampliﬁcation pro-
tocol: denaturation at 95◦C for 10min, followed by 40 cycles
of denaturation at 94◦C for 20s, followed by annealing
and extension at 60◦C for one minute. After the PCR, the
genotype of each sample was determined by measuring the
allele-speciﬁc ﬂuorescence in the ABI Prism 7500 Sequence
Detection System, using SDS 1.1 software for allele discrim-
ination (both Applied Biosystems). To validate the geno-
typing by real-time PCR analysis, 100 PCR products were
subjectto restriction fragmentlength polymorphism (RFLP)
analysiswithMscIrestrictionenzyme(NewEnglandBiolabs,
Beverly, MA, USA) and showed a 100% identical result be-
tween these two genotyping systems as noted in our previous
report [17].
2.3. Statistics Analyses. The Hardy-Weinberg equilibrium
was ﬁrst checked. The statistical diﬀerences between case and
control in genotype and allele frequency were assessed by
chi-square test. The statistical diﬀerences in the genotype
and allele frequency of KD patients with and those without
CALformation,aneurysmformation,patientsrespondingto
IVIG, and those showing resistance were assessed using chi-
square test. SAS 9.1 for Windows was used for data analysis.
3. Results
3.1. DC-SIGN −336 (rs4804803) A/G Polymorphism Was
Associated with the Susceptibility of Kawasaki Disease. In this
study, a total of 278 KD patients were included, of which 35
patients (12.6%) were resistant to initial IVIG treatment, 42
patients (15.1%) had CAL formation and 13 patients (4.7%)
developed coronary artery ﬁstula. In this study, as shown in
Table 1, the diﬀerence of rs4804803 genotype between KD
patients and controls was statistically signiﬁcant (P = 0.004,
dominant model, Table 1). Minor G allele of rs4804803 was
over represented in the KD patients as compared with the
controls (8.1 versus 3.5%).
3.2. No Signiﬁcant Association of DC-SIGN −336 (rs4804803)
A/G Polymorphism with IVIG Treatment Response and CAL
F o r m a t i o ni nK DP a t i e n t s .We further evaluate the rela-
tionship between rs4804803 and the risk of IVIG resistance
or CAL formation. As shown in the Tables 2 and 3, the
frequency of AA genotype was higher in the patients with
IVIG responsiveness (86.0 versus 77.1%) and without CAL
formation (85.2 versus 83.3%). The genotype or allele fre-
quencyofrs4804803,however,wasnotstatisticallyassociated
with IVIG resistance (Table 2)o rC A Lf o r m a t i o n( Table 3).The Scientiﬁc World Journal 3
Table 1: Genotype frequencies for CD209 −336 A/G and Kawasaki disease susceptibility.
Genotype
Case
(%)
(n = 278)
Control subjects
(%)
(n = 243)
Allele
Case
(%)
(n = 278)
Control subjects
(%) (n = 243)
Genotype
P value
Dominant
P value
Recessive
P value
Allelic
P value
CD209
−336 A/G
GG 3 (1.1) 0 (0.0) G 45 (8.1) 17 (3.5) 0.008 0.004 0.104 0.002
GA 39 (14.0) 17 (7.0) A 511 (91.9) 469 (96.5)
AA 236 (84.9) 226 (93.0)
Table 2: Genotyping and allele frequency of CD209 −336 A/G in patients resistant and responsive to intravenous immunoglobulin (IVIG)
treatment.
Genotype Resistant (%)
(n = 35)
Responsive (%)
(n = 243) Allele Resistant (%)
(n = 35)
Responsive (%)
(n = 243)
Genotype
P value
Dominant
P value
Recessive
P value
Allelic
P value
CD209
−336 A/G
GG 1 (2.9) 2 (0.8) G 9 (12.9) 36 (7.4) 0.290 0.171 0.276 0.118
GA 7 (20.0) 32 (13.2) A 61 (87.1) 450 (92.6)
AA 27 (77.1) 209 (86.0)
Table 3: Genotyping and allele frequency of CD209 −336 A/G in patients with coronary artery lesion (CAL) and without CAL.
Genotype CAL (%)
(n = 42)
Without (%)
(n = 236) Allele CAL (%)
(n = 42)
Without (%)
(n = 233)
Genotype
P value
Dominant
P value
Recessive
P value
Allelic
P value
CD209
−336 A/G
GG 0 (0.0) 3 (1.3) G 7 (8.3) 38 (8.1) 0.673 0.760 0.463 0.930
GA 7 (16.7) 32 (13.5) A 77 (91.7) 434 (91.9)
AA 35 (83.3) 201 (85.2)
Table 4: Genotyping and allele frequency of CD209 −336 A/G in patients with ﬁstula or without ﬁstula.
Genotype Fistula (%)
(n = 13)
Without (%)
(n = 265) Allele Fistula (%)
(n = 13)
Without (%)
(n = 265)
Genotype
P value
Dominant
P value
Recessive
P value
Allelic
P value
CD209
−336 A/G
GG 0 (0.0) 3 (1.1) G 2 (9.4) 43 (8.1) 0.921 0.977 0.700 0.939
GA 2 (15.4) 37 (14.0) A 24 (90.6) 487 (91.9)
AA 11 (84.6) 225 (84.9)
3.3. No Signiﬁcant Association of DC-SIGN −336 (rs4804803)
A/G Polymorphism with Coronary Artery Fistula Formation
in KD Patients. To further identify the role of rs4804803 of
CD209 in the pathogenesis of coronary artery ﬁstula in KD
patients, we performed a subset analysis in cases that were
reported as having ﬁstula formation (13/278, 4.7%). Sub-
set analysis between cases with coronary artery ﬁstula and
rs4804803 did not yield any signiﬁcant results (Table 4).
4. Discussion
DC-SIGN is a transmembrane lectin receptor on dendritic
cells with multiple immune modulation function [18] DC-
SIGN canrecognizemanypathogens,suchasviruses(HIV-1,
dengue, and measles virus) [19–21], bacteria (Helicobacter
pylori, Mycobacterium tuberculosis)[ 22], and fungi (Candida
albicans and Aspergillus fumigatus)[ 23] contributing to
generation of pathogen-tailored immune responses and
immunosuppressive response by the MAPK pathway in DCs
[24]. The real cause of KD remains unknown. It is generally
accepted that KD results from an undeﬁned infectious pro-
cess trigger in a genetically predisposed individual [25].
A genetic predisposition is suggested based on clinical and
epidemiologic features [1, 26]. In this study, we investigated
whether the polymorphism of DC-SIGN (CD209) promoter
−336 A/G (rs4804803) was associated with susceptibility
and CAL formation in KD. Our study showed that the allele
−336G was associated with susceptibility to KD. To the
best of our knowledge, this is the ﬁrst study to explore the
association between DC-SIGN polymorphisms and suscep-
tibility to KD.
Immunoglobulin is well known for its defensive role in
pyogenic infection. In addition to its protective role, immu-
noglobulin G (IgG) was also noted to have anti-inﬂamma-
tory eﬀects at high doses. Recently, the α2, 6 sialylated IgG
was reported to interact with a lectin receptor, SIGN-R1
in mice and DC-SIGN in humans, and to trigger an anti-
inﬂammatory cascade. Thus it is reasonable to hypothesize
that a functional SNP in the DC-SIGN molecule will be
involved in the response to IVIG treatment. However, in our
study,wefoundthevariantandhaplotypeof −336A/Ginthe
DC-SIGN genedidnotassociatewiththeoccurrenceofIVIG
resistance or CAL formation in KD. Because of its highly
polymorphic nature and numerous SNPs of DC-SIGN gene4 The Scientiﬁc World Journal
[27–29], further investigation into other candidate SNPs
contributing to KD morbidity is needed. Besides dendritic
cells, IVIG was observed to aﬀect many other cells, including
endothelial cells, monocytes, neutrophils, and T and B cells
[30–32]. The numerous eﬀects of IVIG therapy also partly
explain there not being an association of −336A/G SNP of
the DC-SIGN gene with IVIG resistance in KD.
There were some limitations with regards to this study.
First, the relatively small sample size of this study might pre-
ventsomeofthedetectedassociationsfrombeingstatistically
signiﬁcant. Second, our study results need to be validated
across diﬀerent populations. Since the incidence of KD in
Asian populations is much greater than among Caucasians
[1], the host’s genetic background must be considered in
the study of KD. In our control group, the frequency of the
−336G DC-SIGN gene allele was 3.5%. This result agreed
with previous reports showing very low −336G DC-SIGN
gene allelic frequency in Asians [33, 34]. The highest
−336G allelic frequency was found in African populations
(35–48%), next in Caucasian populations (20%), and the
lowest was observed in Asians [8, 33].
In conclusion, from our study, we found the G allele of
DC-SIGN promoter −336 (rs4804803) to be a risk allele in
the development of KD in a Chinese population. Further
studies to explore the eﬀects of other SNPs of DC-SIGN or
a combination of genes are needed.
Conﬂict of Interests
The authors declare that they have no conﬂict of interest.
Authors Contributions
Hong-Ren Yu and Wei-Pin Chang have equally contributed
to this paper.
Acknowledgments
This paper was supported in part by Grant CCF100-02 (Y. J.
Lin) from the Cardiac Children’s Foundation of the Republic
of China and Grants (NSC 98-2314-B-182A-004-MY3 and
NSC100-2314-B-182A-048-MY3)fromtheNationalScience
Council, Taiwan.
References
[1] J .C.BurnsandM.P .Glod´ e,“Kawasakisyndrome,”Lancet,vol.
364, no. 9433, pp. 533–544, 2004.
[ 2 ]C .L .W a n g ,Y .T .W u ,C .A .L i u ,H .C .K u o ,a n dK .D .Y a n g ,
“Kawasaki disease: infection, immunity and genetics,” Pedia-
tric Infectious Disease Journal, vol. 24, no. 11, pp. 998–1004,
2005.
[3] J. W. Newburger, M. Takahashi, M. A. Gerber et al., “Diag-
nosis, treatment, and long-term management of Kawasaki
disease: a statement for health professionals from the com-
mitteeonrheumaticfever,endocarditis,andKawasakidisease,
council on cardiovascular disease in the young, American
Heart Association,” Pediatrics, vol. 114, no. 6, pp. 1708–1733,
2004.
[4] C. Galeotti, J. Bayry, I. Kone-Paut, and S. V. Kaveri, “Kawasaki
disease: aetiopathogenesis and therapeutic utility of intraven-
ous immunoglobulin,” Autoimmunity Reviews, vol. 9, no. 6,
pp. 441–448, 2010.
[5] J. N. Arnold, M. R. Wormald, R. B. Sim, P. M. Rudd, and R. A.
Dwek, “The impact of glycosylation on the biological function
and structure of human immunoglobulins,” Annual Review of
Immunology, vol. 25, pp. 21–50, 2007.
[ 6 ]R .M .A n t h o n ya n dJ .V .R a v e t c h ,“ An o v e lr o l ef o rt h eI g GF c
glycan: the anti-inﬂammatory activity of sialylated IgG Fcs,”
Journal of Clinical Immunology, vol. 30, no. 1, supplement, pp.
S9–S14, 2010.
[7] A. Marzi, T. Gramberg, G. Simmons et al., “DC-SIGN and
DC-SIGNR interact with the glycoprotein of marburg virus
andtheSproteinofsevereacuterespiratorysyndromecorona-
virus,” Journal of Virology, vol. 78, no. 21, pp. 12090–12095,
2004.
[8] F.O.Vannberg,S.J.Chapman,C.C.Khoretal.,“CD209gene-
ticpolymorphismandtuberculosisdisease,” PLoSONE,vol.3,
no. 1, article e1388, 2008.
[9] Y. Koizumi, S. Kageyama, Y. Fujiyama et al., “RANTES -28G
delays and DC-SIGN −139C enhances AIDS progression in
HIV type 1-infected Japanese hemophiliacs,” AIDS Research
and Human Retroviruses, vol. 23, no. 5, pp. 713–719, 2007.
[10] H. C. Kuo, C. L. Wang, C. D. Liang et al., “Association of lower
eosinophil-related T helper 2 (Th2) cytokines with coronary
artery lesions in Kawasaki disease,” Pediatric Allergy and Im-
munology, vol. 20, no. 3, pp. 266–272, 2009.
[11] H. C. Kuo, C. L. Wang, C. D. Liang et al., “Persistent mono-
cytosis after intravenous immunoglobulin therapy correlated
with the development of coronary artery lesions in patients
with Kawasaki disease,” Journal of Microbiology, Immunology
and Infection, vol. 40, no. 5, pp. 395–400, 2007.
[12] H.R.Yu,H.C.Kuo,J.M.Sheenetal.,“Auniqueplasmaprote-
omic proﬁling with imbalanced ﬁbrinogen cascade in patients
with Kawasaki disease,” Pediatric Allergy and Immunology, vol.
20, no. 7, pp. 699–707, 2009.
[13] S. T. Shulman, J. De Inocencio, and R. Hirsch, “Kawasaki
disease,” Pediatric Clinics of North America, vol. 42, no. 5, pp.
1205–1222, 1995.
[14] H. R. Yu, H. C. Kuo, E. Y. Huang et al., “Plasma clusterin levels
in predicting the occurrence of coronary artery lesions in pa-
tients with kawasaki disease,” Pediatric Cardiology, vol. 31, no.
8, pp. 1151–1156, 2010.
[15] C. D. Liang, H. C. Kuo, K. D. Yang, C. L. Wang, and S. F.
Ko,“CoronaryarteryﬁstulaassociatedwithKawasakidisease,”
American Heart Journal, vol. 157, no. 3, pp. 584–588, 2009.
[16] H. C. Kuo, K. D. Yang, C. D. Liang et al., “The relationship
of eosinophilia to intravenous immunoglobulin treatment
failureinKawasakidisease,”PediatricAllergyandImmunology,
vol. 18, no. 4, pp. 354–359, 2007.
[17] L. Wang, R.-F. Chen, J.-W. Liu et al., “DC-SIGN (CD209) pro-
moter −336 A/G polymorphism is associated with dengue
hemorrhagic fever and correlated to DC-SIGN expression and
immune augmentation,” PLoS Neglected Tropical Diseases, vol.
5, no. 1, article e934, 2011.
[18] S. I. Gringhuis, J. den Dunnen, M. Litjens, B. van het Hof,
Y. van Kooyk, and T. H. Geijtenbeek, “C-type lectin DC-
SIGN modulates toll-like receptor signaling via Raf-1 kinase-
dependent acetylation of transcription factor NF-κB,” Immu-
nity, vol. 26, no. 5, pp. 605–616, 2007.The Scientiﬁc World Journal 5
[19] T. B. H. Geijtenbeek, D. S. Kwon, R. Torensma et al., “DC-
SIGN, a dendritic cell-speciﬁc HIV-1-binding protein that en-
hances trans-infection of T cells,” Cell, vol. 100, no. 5, pp. 587–
597, 2000.
[20] E. Pokidysheva, Y. Zhang, A. J. Battisti et al., “Cryo-EM recon-
struction of dengue virus in complex with the carbohydrate
recognition domain of DC-SIGN,” Cell, vol. 124, no. 3, pp.
485–493, 2006.
[21] L. De Witte, M. Abt, S. Schneider-Schaulies, Y. Van Kooyk,
and T. B. H. Geijtenbeek, “Measles virus targets DC-SIGN to
enhance dendritic cell infection,” Journal of Virology, vol. 80,
no. 7, pp. 3477–3486, 2006.
[22] S. I. Gringhuis, J. den Dunnen, M. Litjens, M. van der Vlist,
a n dT .B .H .G e i j t e n b e e k ,“ C a r b o h y d r a t e - s p e c i ﬁ cs i g n a l i n g
through the DC-SIGN signalosome tailors immunity to
Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori,”
Nature Immunology, vol. 10, no. 10, pp. 1081–1088, 2009.
[23] A. Cambi, K. Gijzen, I. J. M. de Vries et al., “The C-type lectin
DC-SIGN (CD209) is an antigen-uptake receptor for Candida
albicans on dendritic cells,” European Journal of Immunology,
vol. 33, no. 2, pp. 532–538, 2003.
[24] R. Mittal, S. Bulgheresi, C. Emami, and N. V. Prasadarao, “En-
terobacter sakazakii targets DC-SIGN to induce immunosup-
pressive responses in dendritic cells by modulating MAPKs,”
Journal of Immunology, vol. 183, no. 10, pp. 6588–6599, 2009.
[25] M.Lidar,N.Lipschitz,P.Langevitz,andY.Shoenfeld,“Thein-
fectious etiology of vasculitis,” Autoimmunity, vol. 42, no. 5,
pp. 432–438, 2009.
[26] Y. Nakamura, M. Yashiro, R. Uehara, I. Oki, M. Watanabe,
andH.Yanagawa,“EpidemiologicfeaturesofKawasakidisease
in Japan: results from the nationwide survey in 2005-2006,”
Journal of Epidemiology, vol. 18, no. 4, pp. 167–172, 2008.
[ 2 7 ] Y .F .X u ,W .L .L i u ,J .Q .D o n ge ta l . ,“ S e q u e n c i n go fD C - S I G N
promoterindicatesanassociationbetweenpromotervariation
and risk of nasopharyngeal carcinoma in cantonese,” BMC
Medical Genetics, vol. 11, no. 1, article 161, 2010.
[28] S. Kashima, E. S. Rodrigues, R. Azevedo et al., “DC-SIGN
(CD209) gene promoter polymorphisms in a Brazilian pop-
ulation and their association with human T-cell lymphotropic
virus type 1 infection,” Journal of General Virology, vol. 90, no.
4, pp. 927–934, 2009.
[29] M. Ben-Ali, L. B. Barreiro, A. Chabbou et al., “Promoter and
neck region length variation of DC-SIGN is not associated
with susceptibility to tuberculosis in Tunisian patients,” Hu-
man Immunology, vol. 68, no. 11, pp. 908–912, 2007.
[ 3 0 ]T .T h a - I n ,J .B a y r y ,H .J .M e t s e l a a r ,S .V .K a v e r i ,a n dJ .
Kwekkeboom, “Modulation of the cellular immune system by
intravenous immunoglobulin,” Trends in Immunology, vol. 29,
no. 12, pp. 608–615, 2008.
[31] T. Ichiyama, Y. Ueno, M. Hasegawa, A. Niimi, T. Matsubara,
and S. Furukawa, “Intravenous immunoglobulin inhibits NF-
κB activation and aﬀects Fcγ receptor expression in mono-
cytes/macrophages,” Naunyn-Schmiedeberg’s Archives of Phar-
macology, vol. 369, no. 4, pp. 428–433, 2004.
[32] K. Yoshimura, K. Tatsumi, A. Iharada et al., “Increased nitric
oxideproductionbyneutrophilsinearlystageofKawasakidis-
ease,” European Journal of Pediatrics, vol. 168, no. 9, pp. 1037–
1041, 2009.
[33] L. B. Barreiro, O. Neyrolles, C. L. Babb et al., “Promoter varia-
tion in the DC-SIGN-encoding gene CD209 is associated with
tuberculosis,” PLoS Medicine, vol. 3, no. 2, article e20, 2006.
[34] R. Zheng, Y. Zhou, L. Qin et al., “Relationship between poly-
morphism of DC-SIGN (CD209) gene and the susceptibility
to pulmonary tuberculosis in an eastern Chinese population,”
Human Immunology, vol. 72, pp. 183–186, 2011.